Europese Unie - Nederlands - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccins - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. het gebruik van dit vaccin moet gebeuren in overeenstemming met officiële aanbevelingen.

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

a.a.-vet diergeneesmiddelen n.v. - kamfer, (d-vorm); sulfobituminose-ammonium - zalf - kamfer, (d-vorm) 100 mg/g; sulfobituminose-ammonium 100 mg/g, - other therapeutic products - runderen

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

feed farm b.v. - kamfer, (d-vorm); sulfobituminose-ammonium - zalf - other therapeutic products

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

conforma sa-nv - kamfer, synthetisch 20 g/100 g - zalf - kamfer 200 mg/g - antiinflammatory and antirheumatic products, non-steroids

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

kommer-biopharm b.v. - kamfer, (d-vorm); sulfobituminose-ammonium - zalf - kamfer, (d-vorm) 100 mg/g; sulfobituminose-ammonium 150 mg/g, - other therapeutic products - eenhoevigen; herkauwers; honden; katten; knaagdieren; varkens

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

chemicals laif - thymol 8 g; kamfer, synthetisch 0.39 g; levomenthol 0.39 g; eucalyptus globulus labill., blad, essentiële olie 1.72 g - strip voor in de bijenkorf - kamfer 0.39 g; menthol 0.39 g; eucalyptus globulus, olie 1.72 g; thymol 8 g - combinations of other ectoparasiticides for topical use - bij

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

otc medical b.v. linie 13a 6678 pk oosterhout - eucalyptusolie 15 mg/g ; kamfer, (d,l-vorm) 50 mg/g ; majoranaolie 10 mg/g ; terpentijnolie, gerectificeerd 40 mg/g - zalf voor inhalatiedamp - cypresolie ; nootmuskaatolie ; paraffine, hard (e 905) ; paraffine, zacht (e 905) ; thijmolie, - other cold preparations

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

otc medical b.v. linie 13a 6678 pk oosterhout - eucalyptusolie 15 mg/g ; kamfer, (d,l-vorm) 50 mg/g ; levomenthol (l- vorm) 27,5 mg/g ; terpentijnolie, gerectificeerd 50 mg/g - zalf voor inhalatiedamp - cederbladolie ; nootmuskaatolie ; paraffine, hard (e 905) ; paraffine, zacht (e 905) ; thymol, - other cold preparations

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

otc medical b.v. linie 13a 6678 pk oosterhout - bergdenolie 30 mg/g ; dennennaaldenolie van pinus silvestris l. 25 mg/g ; eucalyptusolie 50 mg/g ; kamfer, (d,l-vorm) 100 mg/g ; levomenthol (l- vorm) 27,5 mg/g ; terpentijnolie, gerectificeerd 50 mg/g - zalf voor inhalatiedamp - cederbladolie ; nootmuskaatolie ; paraffine, hard (e 905) ; paraffine, zacht (e 905) ; thymol, - other cold preparations

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratoria qualiphar sa-nv - pinus pinaster aiton, hars, essentiële olie 59 mg/g; menthol 35,4 mg/g; kamfer 59 mg/g - huidspray, oplossing - menthol 35.4 mg/g; turpentijnolie 59 mg/g; kamfer 59 mg/g - various